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BACKGROUND: Fertility is a priority for many young women with breast cancer. Women need to be informed about interventions
to retain fertility before chemotherapy so as to make good quality decisions. This study aimed to prospectively evaluate the efficacy
of a fertility-related decision aid (DA).
METHODS: A total of 120 newly diagnosed early-stage breast cancer patients from 19 Australian oncology clinics, aged 18–40
years and desired future fertility, were assessed on decisional conflict, knowledge, decision regret, and satisfaction about
fertility-related treatment decisions. These were measured at baseline, 1 and 12 months, and were examined using linear mixed
effects models.
RESULTS: Compared with usual care, women who received the DA had reduced decisional conflict (b¼1.51; 95%CI: 2.54 to 0.48;
P¼ 0.004) and improved knowledge (b¼ 0.09; 95%CI: 0.01–0.16; P¼ 0.02), after adjusting for education, desire for children and
baseline uncertainty. The DA was associated with reduced decisional regret at 1 year (b¼3.73; 95%CI: 7.12 to 0.35;
P¼ 0.031), after adjusting for education. Women who received the DA were more satisfied with the information received on the
impact of cancer treatment on fertility (Po0.001), fertility options (P¼ 0.005), and rated it more helpful (P¼ 0.002), than those who
received standard care.
CONCLUSION: These findings support widespread use of this DA shortly after diagnosis (before chemotherapy) among younger breast
cancer patients who have not completed their families.
British Journal of Cancer (2012) 106, 1053 – 1061. doi:10.1038/bjc.2012.61 www.bjcancer.com
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Approximately 3–7% of women with early-stage breast cancer
are under 40 years of age at diagnosis (Australian Institute of
Health and Welfare (AIHW) and Australasian Association of
Cancer Registries (AACR), 2004; Bouchardy et al, 2007; Peate
et al, 2009; American Cancer Society, 2011–2012). Most women
receive adjuvant chemotherapy, which is often associated with
diminished ovarian function (Bines et al, 1996; Goodwin et al,
1999; Minton and Munster, 2002). Fertility information is a
priority for young women with breast cancer but provision of
such information is often inadequate (Partridge et al, 2004; Peate
et al, 2009).
Following diagnosis of early breast cancer, women need to
make rapid decisions regarding fertility interventions before
commencing chemotherapy. Decision making about fertility
preservation is complex with many ill-defined risk factors, such
as fertility-treatment-induced increases in ovarian sex steroid
levels, which are contraindicated in women with breast cancer
(Oktay et al, 2005; Lee et al, 2006; Partridge et al, 2007). Further,
fertility decisions usually need to be made shortly after a new
cancer diagnosis, concurrent with cancer treatment decisions.
Therefore, it is vital that clear and current information about
fertility is provided in a timely manner.
The American Society for Clinical Oncology has recommended
that fertility preservation be discussed early in women’s treatment
trajectory (Lee et al, 2006). It has been previously reported that
fertility-related issues are often inadequately addressed in clinical
management (Biglia et al, 2003; Partridge et al, 2004; Duffy et al,
2005; Thewes et al, 2005). Recent data has indicated that rates of
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fertility referrals are increasing in the United States (Lee et al,
2011), yet another study reported that o25% of US oncologists
report referring patients for fertility preservation, only 38%
reported knowledge of the American Society of Clinical Oncology
guidelines, and o25% reported distributing fertility-related
materials (Quinn et al, 2009). Furthermore, a study among Irish
cancer specialists has reported that awareness of ART success rates
was poor and a barrier to referrals (Collins et al, 2011). In
Australia, there are no clear guidelines for referral despite the
existence of public and private fertility clinics, and fertility
treatment is not available without cost. The complexity of
discussing fertility-related issues, including current relationship
status, plans for children, and the range of fertility-preserving
options available further hinder timely and adequate exchange of
information (Duffy et al, 2005; Quinn et al, 2007, 2008). It is not
surprising that young early breast cancer patients have unmet
fertility-related information needs (Knobf, 2001; Thewes et al,
2003, 2004, 2005; Partridge et al, 2004).
Decision aids (DAs) are educational materials designed to assist
with treatment decision-making, addressing individual values and
preferences (Janis and Mann, 1977). They increase knowledge and
reduce decisional conflict without increasing anxiety (O’Connor
et al, 2009). The efficacy of a DA has not previously been evaluated
in the context of fertility and early breast cancer, in particular the
impact the DA may have on distress (anxiety and depression) and
on other decision-making outcomes (such as, decisional conflict
and regret, and informed choice). Anxiety and depression were
assessed to measure whether receiving detailed, potentially
distressing information about fertility would lead to adverse
emotional outcomes.
The DA is a C5-sized booklet that contains information about
breast cancer and female fertility, and a discussion of the different
fertility options available. It also includes a series of values
clarification exercises that list the advantages and disadvantages of
each treatment option to be rated by participants as an option that
they are either ‘leaning’ towards or against. Development and pilot
testing of the fertility DA has been previously reported (Peate et al,
2011b) and the DA can be found on the Cancer Council of
Australia’s website (Peate et al, 2011a).
The current study prospectively evaluated the efficacy of this DA
compared with usual care among young women diagnosed with
early breast cancer. Specific aims were to:
(i) Compare changes in decision-related outcomes, including
decisional conflict about fertility treatment decisions (primary
outcome) and knowledge, over time.
(ii) Compare decision-related outcomes, including decisional
regret about treatment decisions, and informed choice at
1 and 12 months post diagnosis.
(iii) Examine potential changes in anxiety and depression as a
result of the use of the DA compared to usual care.
METHODS
Participants
Participants were consecutive early breast cancer patients (stage I,
II, and III, excluding ductal carcinoma in situ and metastatic
disease) referred to 1 of 19 oncology clinics around Australia
between 2006 and 2009. Approval was obtained from all
institutional review boards, and all women provided written
informed consent. Inclusion criteria were: 18–40 years of age;
diagnosed with invasive early breast cancer (as defined above);
proficient in English; pre-menopausal at time of diagnosis; not yet
having commenced adjuvant therapy; and interest in having a
child. Eligible women were invited to participate by breast care
nurses (BCNs) at each site within a week of their diagnosis and
before any medical oncologist or fertility specialist appointments.
Study design
The first 81 women recruited across all sites received a guide on
early breast cancer developed for consumers, currently distributed
to women at many clinics as part of usual care (National Breast
Cancer Centre, 2003). This number was approached to account for
attrition. The next 52 participants received the DA in addition to
the consumer guide. A non-randomised trial design was under-
taken to prevent participants sharing brochures.
Procedure
Women were identified and invited to participate, soon after
diagnosis, by the breast care nurses at each site, who were trained
in the recruitment process. After consenting to participate,
participants were given a package containing an invitation letter,
baseline questionnaire, reply-paid envelope, and a sealed envelope
with instructions not to open it until the questionnaire was
completed. Upon completing the questionnaire, participants
were asked to read the consumer guide (usual care control) or
DA, which included completing the values clarification exercises
(intervention), supplied in the sealed envelope before their
oncologist appointment, if possible. Follow-up questionnaires
were posted 1 and 12 months later. Participants were asked to
complete paper-based self-administered questionnaires.
Measures
Demographic, reproductive and disease-related data Age at
diagnosis, relationship status, parity, desire for more children,
and highest level of education attained were recorded at baseline.
Intended decision about fertility treatment Two items, measured
at baseline and 1-month follow-up, asked ‘At this point in time, are
you leaning towardsy’ (a) ‘waiting to see if fertility returns after
treatment’ and (b) ‘in vitro fertilisation’. Participants could opt to
include intended decisions for ‘other’ techniques (not included in
analyses due to limited data).
The following outcome measures were administered at all three
time points:
Decisional conflict scale (DCS): The 10-item low literacy version
of this scale assessed decisional conflict regarding ‘different
fertility treatments’ (O’Connor, 1995). Scores437.5 on the overall
scale (range 0–100) indicate high decisional conflict, which is
characterised by decision delay and/or uncertainty about decision
implementation (O’Connor, 1995).
Knowledge of fertility-related information: The items were
selected based on previous research exploring the unmet fertility-
related needs of this population (Thewes et al, 2005). Ten true-false
items measured knowledge of (i) assisted reproductive techno-
logies; (ii) the impact of different therapy regimens on fertility;
and (iii) the impact of pregnancy after breast cancer on prognosis.
A total knowledge score was calculated (range, 0–10). The scale had
satisfactory internal consistency with Cronbach’s alpha of 0.63.
Hospital anxiety and depression scale: The 14-item Hospital
Anxiety and Depression Scale was used to measure emotional
disturbance (Zigmond and Snaith, 1983; Ibbotson et al, 1994). It
has two subscales measuring anxiety and depression, with each
subscale ranging 0–21 (Zigmond and Snaith, 1983; Ibbotson et al,
1994).
The following outcome measures were administered at the two
follow-up assessments only:
Multidimensional measure of informed choice (MMIC):
This assessed whether women made treatment decisions with
adequate knowledge (based on the Knowledge of Fertility-Related
Information Scale) in accordance with their values, assessed
with an adaptation of the five-item scale to assess attitudes towards
fertility treatment in regard to feeling ‘beneficial’/‘harmful’,
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‘important’/‘unimportant’, ‘a good thing’/‘a bad thing’, ‘pleasant’/
‘unpleasant’, and ‘worthwhile’/‘not worthwhile’ (Michie et al,
2002). Response options ranged from ‘very positive’ (scored as 1)
to ‘very negative’ (scored as 7). The MMIC was scored in
accordance with the instructions provided by the developers – a
total score was obtained by summing an individual’s items (scores
ranged from 5 to 35) (Michie et al, 2002). Two groups were
classified as having made an informed choice: those who scored
above the sample median on the knowledge of fertility-related
information scale, had a positive attitude towards fertility
treatments, and decided to undergo fertility treatments by the
time of follow-up, and those who had a good knowledge score, a
negative attitude towards fertility treatments, and did not undergo
fertility treatments (Michie et al, 2002). All other women were
categorised as having made an uninformed choice. The MMIC has
good internal consistency (Cronbach’s alpha of 0.66 and 0.81
for the knowledge and attitudes subscales, respectively, for
this study) and excellent predictive and discriminant validity
(Michie et al, 2002).
Decision regret scale (DRS) – fertility interventions This five-
item scale was used as a quantifier of health care decision regret
(Brehaut et al, 2003) about fertility treatment decisions, with
higher total scores indicating more regret (range 0–100).
Use of materials: One item determined whether, and the extent
to which, materials were read.
Satisfaction with, and helpfulness of, educational materials:
Three items elicited satisfaction with, and perceived helpfulness of,
the educational materials.
Actual decision: Participants were asked about whether they
received adjuvant treatments and fertility-preserving interventions.
Partner’s involvement: Four items assessed the use of the
educational materials by, and impact on any partners. These
included whether the educational materials were shared with the
partner; the extent to which partners had read the materials;
whether the materials stimulated discussion between partners; how
useful the partners considered the booklet; and whether the
partner contributed to the decision-making process about fertility-
related issues.
Clinician discussion and referral: Four items assessed frequency
of contact, thoroughness of fertility-related discussions, and extent
to which discussion and fertility referrals were prompted by study
materials.
The following outcome measure was administered at the last
follow-up assessment only:
DRS – cancer treatments (Brehaut et al, 2003): This was used to
assess regret about decisions made about cancer treatments.
Higher total scores indicated greater regret (range 0–100).
Statistical analyses
An intention to treat analysis was undertaken. Linear mixed effects
models (with random baseline measurements and slopes) were
used to examine the effect of the DA on outcome variables assessed
across three occasions (DCS, knowledge, anxiety, and depression),
adjusting for potential confounders and for curvilinear change
(time2). Confounders (education, relationship status, parity, and
desire for more children) were incorporated into a statistical
model if they were theoretically relevant and resulted in a 420%
change in the treatment effect estimates. Confounders were also
included if they were associated with substantial reduction in
Akaike’s Information Criterion and Schwarz’s Bayesian Informa-
tion Criterion. Depression scores were log-transformed, given their
skewed distributions. For variables collected at 1 and 12 months
only, raw scores were used for analyses. Linear regression was used
to assess differences between groups for continuous variables
(DRS), and logistic regression was used to assess group differences
for binary outcome variables (MMIC).
The target sample size was 64 participants in each group.
This would provide sufficient power (80%) to detect a difference
of 0.5 between groups (i.e., a medium effect size; Cohen, 1988) in
the primary outcome variable (DCS). This has been considered
clinically important in a range of cancer-related scenarios (Frost,
2002).
RESULTS
Response rates
A total of 145 eligible women were invited to participate (Figure 1),
of these 70 women in the control group and 44 in the intervention
group returned the baseline questionnaire. The final questionnaire
was returned by 96 women (60 usual care and 36 intervention
participants). The target sample size was not achieved as a result of
slower than anticipated recruitment, and the trial was stopped
before the target sample size in the DA group was achieved.
Participants who completed at least one questionnaire (N¼ 120,
72 and 48 participants allocated to usual care and the DA,
respectively) were included in the analysis. This represented 83.3%
of eligible subjects and 90.2% of those agreeing to participate. Due
to slower than anticipated recruitment rates, the study was closed
before reaching the target sample size; however, the sample size
was large enough to detect differences.
Participant characteristics
There were no significant differences in demographics between DA
and usual care groups (Table 1). Most participants did not have
children (69%, N¼ 79). Of this group, 82% (N¼ 65) reported that
they planned to have children or that they were unsure whether
they wished to have any children (18%, N¼ 14). Of the 35
participants who already had children, 46% (N¼ 16) definitely
planned to have more children and the rest (54%, N¼ 19) were
unsure. Overall, most participants reported that they planned to
have (more) children (71%, N¼ 81).
Unadjusted mean scores and percentages are presented for all
outcomes separately for the DA and usual care groups in Table 2.
The majority of participants (96%) who received the DA
reported reading the materials, compared with 83% of participants
allocated to usual care. The extent to which this was read is shown
in Table 3.
Decisional conflict scale
Those who received the DA had a greater reduction in decisional
conflict than those who received usual care over 12 months
(Figure 2). Using a mixed effects model with random baseline
measurements, the effect of the DA was significant after
adjustment for education, desire for more children, and un-
certainty at baseline (treatment group by time interaction:
b¼1.51; 95%CI: 2.54 to 0.48; P¼ 0.004), in a curvilinear
manner (b¼ 2.42; 95%CI: 1.88–2.96; Po0.001). Adjusted results
identified a negligible mean difference of 1.46 in DCS between
groups at 1 month (s.e.¼ 3.66; 95%CI: 5.77–8.69; P¼ 1.00).
Decisional conflict scale scores were 15.30 units lower in the DA
group at 12 months (s.e.¼ 5.52; 95%CI: 26.17 to 4.43; P¼ 0.02).
Knowledge of fertility-related information
Figure 3 shows the change in correctly answered questions from
baseline to 12 months in both study arms, and shows that across
most items there was an increase in correct responses from
baseline to final follow-up.
Use of the DA significantly improved fertility-related knowledge
(Figure 4). Using a random baseline and slopes mixed effects
model with adjustment for education, desire for more children and
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uncertainty about the decision at baseline, a significant improve-
ment in knowledge was noted (treatment group by time interaction:
b¼ 0.09; 95%CI: 0.01–0.16; P¼ 0.02) in participants who received
the DA, compared with the usual care group. Adjusted results
identified a negligible mean difference of 0.01 in knowledge scores
between groups at 1 month (s.e.¼ 0.032; 95%CI: 0.65 to 0.64;
P¼ 0.99). Knowledge scores were 0.94 units lower in the DA group
at 12-month follow-up (s.e.¼ 0.44; 95%CI: 0.08–1.81; P¼ 0.03).
Multidimensional measure for informed choice
There were no significant differences in the proportions of
participants who made an informed vs an uninformed choice
about fertility based on group allocation at 1 month (OR¼ 2.12;
95%CI: 0.32–2.26; P¼ 0.75), and at 12-month follow-up
(OR¼ 4.41; 95%CI: 0.59–3.75; P¼ 0.10), after adjusting for
relationship status, education, parity, and desire for more children.
Hospital anxiety and depression scale
There was no significant difference in anxiety between treatment
groups after adjusting for education, parity, and desire for more
children (treatment group by time interaction: b¼ 0.02; s.e., 0.06;
95%CI: 0.10 to 0.14; P¼ 0.73) or depression (treatment group by
time interaction: b¼ 0.09; 95%CI: 0.03 to 0.21; P¼ 0.14,
adjustment unnecessary).
Decisional regret scale
At 1 month, DRS scores regarding fertility-related decisions were
not significantly different between groups (b¼ 4.75; 95%CI: 2.7
Table 1 Demographic characteristics (N¼ 120)
Control Intervention Total
Variable N
Mean
(s.d.) N
Mean
(s.d.) N
Mean
(s.d.)
Age in years 72 33.8 (4.0) 48 32.3 (4.7) 120 33.23 (4.3)
Relationship length in yearsa,b 23 4.6 (3.9) 18 4.4 (3.3) 41 4.49 (3.6)
% % %
Relationship statusa
Committed relationship 53 74.6 36 76.6 89 75.4
Not in a committed relationship 18 25.4 11 23.4 29 24.6
Parity
No 46 63.8 36 75.0 79 69.3
Yes 26 36.1 12 25.0 35 30.7
Highest level of education
High school only 13 18.3 5 10.6 18 15.3
Certificate/diploma 18 25.4 8 17.0 26 22.0
Undergraduate degree 27 38.0 20 42.6 47 39.8
Postgraduate degree 13 18.3 14 29.8 27 22.9
Medical or allied health training
No 59 83.1 39 83.0 98 83.1
Yes 12 16.9 8 17.0 20 16.9
Stage
Stage I 7 12.1 3 7.0 10 9.9
Stage II 18 31.0 15 34.9 33 32.7
Stage III 33 56.9 25 58.1 58 57.4
aSeveral participants did not provide information for this item. bMedian¼ 3.0,
inter-quartile range: 2.0 –5.5 years.
Assessed for eligibility and
invited to participate (n =145) Declined (n =12)
 Difficult to follow-up (n =3)
 Information overload (n =2)
 Ill health (n =2)
  Concentrating on cancer Tx (n =1)
 Feeling vulnerable about fertility
  issues (n =1)
  Husband didn’t want information
  (n =1)
 No reason given (n =2)
Allocated to control (n =81)*
Returned questionnaire 1 (n =70)
Did not return Q1 (n =6)
 Withdrew before Q1 (n =4)
 Non-responders (n =2)
Allocated to intervention (n =52)*
Returned questionnaire 1 (n =44) 
Did not return Q1 (n =4)
 Withdrew before Q1 (n =1)
 Non-responders (n =3)
Returned questionnaire 2 (n =45)
Did not return Q2 (n =2)
 Withdrew after Q1 (n =1)
 Non-responders (n =1)
Returned questionnaire 2 (n =65)
Did not return Q2 (n =7)
 Withdrew after Q1 (n =2)
 Non-responders (n =5)
Allocation
Enrolment (n =133)
1-Month
follow-up
12-Month follow-
up
Returned questionnaire 3 (n =36)
Did not return Q3 (n =10)
  Withdrew after Q2 (n =2)
 Deceased (n =0)
 Non-responders (n =8)
Returned questionnaire 3 (n =60)
Did not return Q3 (n =10)
 Withdrew after Q2 (n =0)
 Deceased (n =1)
 Non-responders (n =9)
Figure 1 Participant flowchart. Q1, questionnaire one; Q2, questionnaire two; Tx, treatment; *four participants who were allocated to the intervention
and five participants to the control did not respond to any questionnaires and have not been included in the statistical anaylses.
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to 12.22; P¼ 0.21), or after adjusting for education (b¼ 5.40;
95%CI: 2.19 to 12.99; P¼ 0.16). After adjusting for education,
participants who received the DA had significantly lower
decisional regret at 12 months (b¼3.73; 95%CI: 7.12 to
0.35; P¼ 0.031).
Satisfaction with information
Sixty-seven percent of participants receiving usual care and 70.5%
of participants allocated the DA were satisfied with the information
provided on the impact of breast cancer treatment on fertility.
Similarly, 54.4% and 77.3% were satisfied with the information
given on the impact of treatment and fertility options, respectively.
Compared with participants who received usual care, participants
Table 2 Dependent variable mean scores and proportions on the DCS,
HADS, DRS, and multidimensional measure of informed choice scale
Control Intervention
Unadjusted
analysisa
N Mean (s.d.) N Mean (s.d.) b P-value
Knowledge score
T0 69 5.2 (2.13) 44 5.0 (2.61) 0.08 0.03
T1 65 6.3 (2.28) 44 7.0 (2.16)
T2 59 5.9 (1.92) 33 6.9 (2.01)
DCS
T0 70 47.2 (30.98) 44 51.6 (32.76) 1.43 0.007
T1 64 23.1 (30.56) 45 16.6 (26.48)
T2 58 29.3 (30.96) 34 14.7 (23.74)
HADS: depression scale
T0 70 5.1 (3.71) 44 4.6 (4.72) 0.02 0.15
T1 65 5.0 (3.38) 45 5.3 (4.68)
T2 59 3.2 (3.18) 33 4.0 (4.94)
HADS: anxiety scale
T0 70 8.9 (4.32) 44 8.5 (4.40) 0.04 0.56
T1 65 7.8 (3.71) 45 7.3 (4.92)
T2 59 7.0 (4.52) 33 7.1 (4.27)
DRS: fertility
T1 61 19.7 (18.86) 43 24.4 (19.00) 4.75 0.21
T2 57 49.1 (8.24) 32 45.8 (8.97) 3.34 0.047
DRS: cancer
T2 58 47.8 (7.79) 34 46.5 (7.23) 0.08 0.43
Proportional data for dichotomous variables (%) OR
Multidimensional measure of informed choice
T1 37 60.7% Informed 22 64.3% Informed 3.22 0.071b
T2 29 51.8% Informed 20 64.5% Informed 5.44 0.25b
v2
Actual fertility treatmenta
In vitro fertilisation
T2 53 24.5% 33 30.3% 0.63 0.43
‘Wait and see’
T2 57 61.4% 33 66.6% 0.78 0.38
Actual cancer treatment
Radiotherapy
T2 59 78.0% 35 77.1% 0.33 0.87
Chemotherapy
T2 59 84.7% 35 82.9% 0.15 0.70
Endocrine therapy
T2 59 66.1% 34 70.6% 0.58 0.45
Abbreviations: DCS¼ decisional conflict scale; DRS¼ decisional regret scale; HADS¼
hospital anxiety and depression scale; s.d.¼ standard deviation; T0¼ baseline; T1¼ 1
month; T2¼ 12 months. aUsing a mixed effects model with random baseline measure-
ments, this value represents treatment group by time interaction, unadjusted for
confounders. bUsing a linear or logistic regression models, unadjusted for confounders.
Table 3 Extent to which information materials given as part of this study
were read
Control (%) DA (%)
Not at all 17 5
Yes, briefly 8 14
Yes, just the parts I felt were relevant 22 25
Yes, quite thoroughly 34 27
Yes, from cover to cover 19 29
Abbreviation: DA¼ decision aid.
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Figure 2 Mean DCS scores over the three data collection points.
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Figure 3 Change in the percentage of correct answers in the knowledge
scale from baseline to 12 months, shown in order of the greatest difference
between groups. Key: (1) IVF (in vitro fertilisation) has highest success rate
of fertility options (True); (2) some fertility procedures are still
experimental and not widely available (true); (3) pregnancy after breast
cancer treatment is safe for mother and baby (true); (4) impact of
chemotherapy on fertility is not dependent on age (false); (5) IVF will not
delay cancer treatment (false); (6) pregnancy after breast cancer treatment
will increase chance of recurrence (false); (7) hormonal therapy will not
cause infertility except for time spent on treatment (true); (8) many breast
cancers depend on hormones to grow – thus some fertility drugs are not
recommended (true); (9) fertility treatment can be costly (true); (10)
chemotherapy impacts on fertility by depleting eggs in the ovaries (true).
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allocated the DA were significantly more satisfied with the
materials they received on the impact of breast cancer treatment
on fertility (w2¼ 15.49; Po0.001) and on the different fertility
options available (w2¼ 10.66; P¼ 0.005). Participants were also
significantly more likely to score the DA more highly on a
helpfulness scale in terms of making fertility-related decisions
(w2¼ 0.61; P¼ 0.002).
Partner’s involvement
The impact of the DA on partner’s involvement in reading and
discussing the educational materials and contributing to fertility-
related decision making is shown in Table 4. Partner’s involvement
did not significantly differ between groups. Partners were
considered to be ‘very’ or ‘extremely’ involved in the decision-
making process (77.6%) with most participants rating the DA as
‘somewhat’ or ‘very’ useful to partners (74.2%).
Fertility-related discussions with oncologists
Perceived thoroughness of discussions with oncologists and the
extent to which the discussions were prompted by the educational
materials are reported in Table 5. Most women had discussed fertility
to some extent with their medical oncologists (92.5% of controls and
97.7% of women who received the DA, w2¼ 1.50; P¼ 0.47).
Referrals to fertility specialists
Sixty-two percent of participants who received the DA and 55.6%
allocated to usual care were referred to a fertility specialist
(w2¼ 0.48; P¼ 0.49). One participant in each group sought a
fertility specialist, although these patients were not referred by
their oncologists. Of those who received a referral to a fertility
specialist, 91.4% of controls consulted or were planning to see a
fertility specialist, compared with 97.7% participants who received
the DA (w2¼ 0.71; P¼ 0.40).
Intended decisions and fertility treatment uptake
Leaning towards the ‘wait and see’ option did not change
significantly from baseline to 1 month between groups
(P¼ 0.31). Additionally, no differences in change scores were
observed for intention to undergo IVF between groups (P¼ 0.42).
For the total patient sample, 79.7% of controls reported having
made a decision about fertility treatment at 1 month compared
with 91.1% of participants who were allocated the DA (w2¼ 2.62;
P¼ 0.11). At 12 months, 71.2% of participants allocated to usual
care and 76.5% of participants allocated to the DA had made a
decision about fertility preserving options (w2¼ 0.84; P¼ 0.36).
DISCUSSION
This study is the first to report the impact of a fertility DA
on decisional conflict, decision regret, and fertility choices in
young breast cancer patients. The DA reduced decisional conflict
about fertility-related treatment options and reduced decisional
regret about fertility treatments compared with usual care over
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Figure 4 Mean knowledge scale scores over the three data collection
points.
Table 4 Partner involvement in sharing of materials, discussion, and decision making
Control Intervention
Item Responses N % N % v2 P-value
Materials read by partners Yes 33 67.3 17 51.2 2.08 0.15
No 16 32.7 16 48.5
Thoroughness in which partner read the informationa Briefly 9 29.4 6 33.3 0.91 0.34
Just relevant parts 8 23.5 6 33.3
Quite thoroughly 13 38.2 6 33.3
Cover to cover 3 8.8 0 0.0
Discussions stimulated by the materials Yes 17 36.2 12 38.7 0.052 0.82
No 30 63.8 19 61.3
Perceived usefulness of the material for the partnerb Not at all 2 5.3 3 10.7 0.48 0.49
Not very 9 23.7 3 10.7
Somewhat 16 42.1 14 50.0
Very useful 11 28.9 8 28.6
Partner contribution to fertility-related decision makingc Yes 43 87.8 30 93.8 — —
No 6 12.2 2 6.2
Perceived level of partner involvement in fertility-related treatment decisionsd Not at all 0 0.0 0 0.0 0.042 0.84
A little 4 9.3 4 13.3
Quite 4 9.3 5 16.7
Very 13 30.2 7 23.3
Extremely 22 51.2 14 46.7
aDue to small cell sizes, for w2 analyses responses were grouped into ‘briefly and just relevant parts’ and ‘quite thoroughly and cover to cover’. bDue to small cell sizes, for w2
analyses responses were grouped into ‘not at all and not very’ and ‘somewhat and very useful’. cDue to small cell sizes statistical tests could not be conducted. dDue to small cell
sizes, for w2 analyses responses were grouped into ‘not at all, a little and quite’ and ‘very and extremely’.
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12 months. The DA also improved fertility-related knowledge.
The reduction in decisional conflict and improvements in knowl-
edge may be considered clinically important (Ringash et al, 2007).
It is likely that the DA achieved these outcomes by providing
more comprehensive information about fertility options and by
facilitating timely and personalised decision making (O’Connor
et al, 1998). Lower decisional regret indicates reduced distress or
remorse after a decision (Brehaut et al, 2003). Ultimately, these
outcomes indicate that access to the DA increased satisfaction
with choices made and enabled women to feel more informed
about their options and clearer regarding their personal values
(O’Connor et al, 2009).
Access to the DA did not impact on uptake of fertility-
preserving interventions. Uptake of fertility interventions is not
only dependent on information, but also on personal circum-
stances (such as having a male partner), availability and cost of
interventions, previous fertility as well as religious and personal
beliefs (Lee et al, 2006; Dutney, 2007; Jukkala, 2009; Ata and Seli,
2010; Eisenberg et al, 2010; Hershberger and Pierce, 2010). In
addition, uptake of interventions is likely to be influenced by
clinician recommendations (Young, 1996a, b; Cyrus-David and
Strom, 2001; Bober et al, 2004; Taylor and Taguchi, 2005;
McGregor et al, 2007). Little is known about how and why women
and their partners make decisions about fertility interventions
following a cancer diagnosis, or how clinicians decide who to refer
to a fertility specialist. In particular, the relative influence of
patient wishes and clinical recommendation is poorly understood.
It is likely that patients are highly influenced by clinical recom-
mendations regarding fertility interventions, particularly from
their medical oncologist (Silvestri et al, 2003; Lam et al, 2005).
Thus, it is important to provide cancer clinicians with accurate
information about fertility options so that patients are advised
and referred appropriately. Improved understanding of how onco-
logists make decisions about fertility specialist referral is needed.
Reported discussions with oncologists and referrals to specia-
lists did not differ, with or without the DA. Our findings suggested
that most medical oncologists discussed fertility with breast cancer
patients of reproductive age. These statistics are higher than the
rate of B70% reported in previous studies (Partridge et al, 2004;
Thewes et al, 2005), and may reflect selection bias in clinicians who
participated in our study. A national survey of American
oncologists reported that those with favourable attitudes towards
fertility preservation were nearly twice as likely to discuss the
issue, compared with those who had unfavourable attitudes, with
male oncologists approximately half as likely to refer patients as
their female colleagues (Quinn et al, 2009).
Compared with participants who received usual care, those with
access to the DA reported higher rates of satisfaction with the
fertility information received (470%), which is above the 51%
previously reported as having their concerns addressed adequately
(Partridge et al, 2004). Limited discussion may be the result
of women or their clinicians feeling uncomfortable about the
topic, particularly as the primary concern for most is the cancer
diagnosis and treatment. Younger breast cancer patients may
expect that their health care providers, as the experts, will discuss
all that is relevant without prompting, in which case the opinion
of the oncologist regarding fertility may be crucial. Fertility
treatments are rapidly evolving. The level of current knowl-
edge of oncologists about potential fertility preserving options
remains unknown. All participants in this study were considering
pregnancy in the future, but only half were referred to a fertility
specialist, who could offer fertility-preservation techniques. This is
greater than the reported rate of 425% referrals to fertility
specialists reported in a 2009 study of a random sample of
oncologists in the United States (Quinn et al, 2009). Again, this
may reflect either a selection bias of participating oncologists, or a
genuine increase in fertility awareness among oncologists. The
same study reported that o25% of clinicians distributed fertility
preservation materials (Quinn et al, 2009). In comparison, all
participants in our study were given fertility information, either
the control booklet or DA, which may have been the impetus for a
higher referral rate. Though clinic staff was trained in recruitment
procedure to minimise variation across sites, we acknowledge that
there is the potential that different clinicians’ attitudes may
influence decision making. The numbers recruited at each site for
this study were limited; thus, we lacked the capacity to compare
individual effects. More information is needed about how breast
cancer specialists approach fertility issues and how the latest
information about fertility can be effectively provided to
oncologists, and subsequently delivered to patients (including
involving patients in research).
In addition to the limitations discussed above, the non-
randomised design of the study may lead to bias. However, studies
in similar populations using this study design have not shown bias
as a result of time (Goodwin et al, 1999). Additionally, the target
sample size was not achieved most likely a result of slower than
anticipated recruitment as a consequence of strict eligibility
criteria (age, desire for future fertility, and not yet started adjuvant
treatment). It was possible that some women who were eligible for
study participation were not recruited in the short time between
diagnosis and commencing treatment. There is also the potential
that low numbers were a result of the fact that women were
Table 5 Reported details about discussions with medical oncologists about fertility related issues
Control Intervention
Item Responses N % N % v2 P-value
Thoroughness of fertility-related discussions with oncologista Not at all 4 6.2 1 2.3 1.50 0.47
Briefly 18 27.7 19 43.2
Moderately 22 33.8 12 27.3
Quite a bit 13 20.0 9 20.5
Extensively 8 12.3 3 6.8
Who was the discussion initiated by?b Patient 25 38.5 16 37.2 o0.001 1.00
Clinician 36 55.4 23 53.5
Not discussed 4 6.2 4 9.3
Extent to which discussion was prompted by educational materialsa Not at all 28 43.1 12 26.7 1.28 0.53
A little bit 12 18.5 11 24.4
Moderately 16 24.6 15 33.3
Quite a bit 7 10.8 4 8.9
Very much 2 3.1 3 6.7
aDue to small cell sizes, for w2 analyses responses were grouped into ‘not at all and briefly’, ‘moderately’, and ‘quite a bit and extensively’. bw2 analyses excluded those in which
fertility was not discussed.
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approached at a highly stressful time. An increased sample may
have improved the power to detect a difference where trends were
seen (MMIC). Nevertheless, the sample size obtained appeared
large enough to detect a statistically significant result in the
primary outcome variable, DCS. This may have been because the
actual treatment effect was greater than originally anticipated.
Our results raise some interesting questions that may need
further exploration. Most of our participants reported that their
partners were involved in the fertility treatment decision-making
process, yet very little is known about how partners perceive their
role despite fertility-related decisions being a decision for both
parties. Understanding the mechanisms of fertility-related decision
making should incorporate this factor.
Within individual items of our knowledge scale there were
improvements of varying extent. Further exploration of the
specific informational domains would assist in improving the
information delivered and improve the DA. Other considerations
include that the DA will require regular updating as reproductive
technologies advance, bringing ongoing costs. Online resources
may facilitate updating and reduce costs. Also, the DA is currently
available only in English and is not appropriate for culturally and
linguistically diverse populations. Further research into these
issues would further advance support this body of work.
CONCLUSION
We have shown that this fertility DA reduced decisional conflict
and regret about fertility-related treatment options in young breast
cancer patients. Lower decisional conflict and regret indicate
increased satisfaction with choices with respect to personal values.
The DA also improved fertility-related knowledge, which is an
important aspect of informed decision making. The DA also
improved satisfaction with information received and was consi-
dered helpful by patients. These findings suggest that this DA
should be widely distributed to young breast cancer patients
considering future pregnancies before chemotherapy.
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